Diagnosis and Management of Type 2 Diabetes and Prediabetes

Primary Care - Clinics in Office Practice

Volumn 34, Issue 4, 2007, Pages 731-759

  Unger, Jeff ^a  

^a Diabetes and Headache Intervention Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACTOSPLUSMET; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; INSULIN; JANUMET; MEGLITINIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; PRAVASTATIN; RAMIPRIL; REPAGLINIDE; RIOMET; ROSIGLITAZONE; SECRETAGOGUE; SITAGLIPTIN; SULFONYLUREA; TROGLITAZONE; UNCLASSIFIED DRUG;

DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SINGLE DRUG DOSE;

DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; HUMANS; INSULIN; MALE; MASS SCREENING; PREDIABETIC STATE; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 36549069698     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2007.07.007     Document Type: Review

References (44)

1. American Diabetes Association. Available at: http://www.diabetes.org/diabetes-statistics.jsp. Accessed September 1, 2007.
2. National diabetes fact sheet: United States 2005. Centers for Disease Control and Prevention. Available at: www.ndep.nih.gov/diabetes/pubs/2005_National_Diabetes_Fact_Sheet.pdf. Accessed August 1, 2006.
3. Gahagan S., and Silverstein J. Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. American Academy of Pediatrics Committee on Native American Child Health. Pediatrics 112 (2003) e328
4. Casey D.E., Haupt D.W., Newcomer J.W., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 suppl 7 (2004) 4-18
5. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry 160 (2003) 284-289
6. Unger J. Managing mental illness in patients with diabetes. Practical Diabetology 25 2 (2006) 44-53
7. Unger J. Intensive management of type 2 diabetes. Emerg Med 33 (2001) 28-34
8. Fagot-Campagna A., Pettitt D.J., Engelgau M.M., et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 136 (2000) 664-672
9. Beck Nielsen H., and Groop L.C. Metabolic and genetic characterization of prediabetic states: sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 94 (1994) 1714-1721
10. Gambert S.R., and Pinkstaff S. Emerging Epidemic: diabetes in older adults: demography, economic impact, and pathophysiology. Diabetes Spectrum 19 (2006) 221-228
11. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13 Suppl 1 (2007) 10
12. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
13. DECODE Study Group, and European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 26 (2003) 688-696
14. Khaw K.T., Wareham N., Luben R., et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322 (2001) 15-18
15. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
16. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
17. Long S.D., O'Brien K., MacDonald Jr. K.G., et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 17 (1994) 372-375
18. Naslund E., Backman L., Holst J.J., et al. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 8 (1998) 253-260
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
20. Lee Y., Hirosel T., Ohneda M., et al. Beta cell lipotoxicity of non-insulin dependent diabetes mellitus of obese rats: impairment in adipocyte-beta cell relationships. Proc Natl Acad Sci USA 91 (1994) 10878-10882
21. Unger J. Managing type 2 diabetes in adults. In: Unger J. (Ed). Diabetes management in primary care (2007), Lippincott, Williams and Wilkins, Philadelphia 118-191
22. Xiang A.H., Peters R.K., Kjos S.L., et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55 2 (2006) 517-522
23. Saydah S.H., Byrd-Holt D., and Harris M.I. Projected impact of implementing the results of the Diabetes Prevention Program in the U.S. population. Diabetes Care 25 (2002) 1940-1945
24. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic (beta)-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
25. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
26. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
27. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland coronary prevention study. Circulation 103 (2001) 357-362
28. Gerstein H.C., Yusuf S., Bosch J., et al. (DREAM [Diabetes Reduction Assessment with ramipril and rosiglitazone Medication]). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
29. Unger J. Assessing glycemic control using home blood glucose monitoring, continuous glucose sensing, and glycated hemoglobin (A1C) testing. In: Unger J. (Ed). Diabetes management in primary care (2007), Lippincott, Williams and Wilkins, Philadelphia 321-362
30. Monnier L., Collette C., Dunseath G.J., et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30 (2007) 263-269
31. Perkins J.M., and Davis S.N. The rationale for prandial glycemic control in diabetes mellitus. Insulin 2 (2007) 52-60
32. Sayday S.H., Eberhardt M.S., Loria C.M., et al. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 156 (2002) 714-719
33. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
34. Home P.D., Jones N.P., Pocock S.J., et al., (RECORD Study Group). Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 24 (2007) 626-634
35. GlaxoSmithKline Avandia rosiglitazone maleate [package insert]. Available at: http://www.fda.gov/cder/drug/infopage/rosiglitazone_label20070814.pdf. Accessed September 14, 2007.
36. Lincoff A.M., Wolski K., Nicholls S.J., et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 298 10 (2007) 1180
37. Riddle M.C., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
38. Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
39. Meneghini L, Koehnen C, Weng W, et al. The usage of a simplified self-titration dosing guideline for insulin detemir in patients with type 2 diabetes-results of the 303 algorithm study. Presented (abstract # 197-OR) at the 67th annual meeting of the American Diabetes Association. Chicago (IL), June 23-26, 2007.
40. Unger J. Physiologic insulin replacement therapy. In: Unger J. (Ed). Diabetes management in primary care (2007), Lippincott, Williams and Wilkins, Philadelphia 192-264
41. Hermansen K., Colombo M., Storgaard H., et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 25 (2002) 883-888
42. Bretzel R.G., Arnold S., Medding J., et al. A direct efficacy and safety comparison of insulin aspart, humansoluble insuling, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 27 (2004) 1023-1027
43. Garber A.J., Wahlen J., Wahl T., et al. Attainment of glycaemic gols in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 8 1 (2006) 58-66
44. Ceriello A., Piconi L., Quagliaro L., et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 28 (2005) 632-637